 All right. I'd like to welcome everyone to Genomic Medicine 5. My name is Rex Chisholm, and I'm going to co-chair this meeting together with Terry Minolio from the Human Genome Research Institute. Want to thank everybody for coming. We think we've assembled a really great meeting today that we're all going to learn a lot from. This is the fifth in a series of meetings, and we've actually planned out as far as a sixth meeting, which you'll hear about in a bit. Genomic Medicine 1 was held in Chicago in June of 2011, and that was really an attempt to get everybody that was actually, from institutions that were actually doing genomic medicine implementation projects, to just hear from each other and see if there was enough there for us to move forward with activities in the area of genomic medicine. We were actually all very impressed with how much there there was, and that recently was published as a very nice paper summary that came out of that. Genomic Medicine 2 was held in December of 2011 here in Bethesda, and the goal there was to develop collaborative projects and task forces, and there was a lot of time spent thinking about what the areas that needed attention if we were going to actually implement genomic medicine going forward. Genomic Medicine 3 held in Chicago in May of 2012 was one of the first follow-ups from what we learned in Genomic Medicine 2, which was that we needed to really think about engaging stakeholders from the healthcare enterprise. We had some of the leading organizations that actually provide healthcare who were very actively involved in that session. GM4 was held in Dallas last January, and that was the second phase of that sort of plans that emerged from the GM2 meeting, which was the need to engage professional societies and other disease-oriented organizations, and understand what their interests were in the area of genomic medicine and what they thought about implementation. And a very exciting activity that emerged from that was a steering committee that's actually coordinating activities and leveraging ongoing interactions between those professional societies, and you'll hear a little bit more about that later. So then this meeting is also a follow-on from one of the areas that we thought was really important in the Genomic Medicine 2 meeting, which is really to begin to understand U.S. government agency perspectives. Obviously, the federal government's an important participant in healthcare, provides a lot of healthcare itself. We're delighted to see so many representatives, for example, from the armed services who are here today that have huge healthcare operations. So our goal here is to hear from you and to begin to learn a little bit about what, from your perspective, current needs and gaps are in applying genomic medicine, to understand what activities you have in progress or are planning, to understand what obstacles you've encountered or anticipate, to understand how NHGRI and the NIH can facilitate or expand your activities if that's helpful to you. One of the roles, as you can tell from this short introduction already, is that NHGRI has played an important role as a convener of groups, and that seems to be actually been very helpful. And then who else should be at the table that isn't at the table as we move forward? So that's what we hope we'll be able to discuss during the day. And then we have some thoughts about what some possible outcomes might be, but these will get developed during the course of the next two days. Always white papers seem to be an important element to think about what the needs in the U.S. are and possible approaches. And you were all provided in advance of this meeting some information about federal or a national approach that the U.K. has taken to this project. And actually, GM6 is going to be a follow-up with international groups and what their activities are in the area of genomic medicine. We hope to find and identify commonalities between the agencies that are presenting here and see if we can expand those into collaborative activities. We want to hear about initial use cases that we might come to agreement that are things that we should pursue. We should think about how to plan communications and collaborations across agencies as we move forward. One possible model, it will be this steering committee approach that we've taken with the biomedical society and the professional societies. And then needs and goals for interaction. And especially as we think about the international meeting, which will be held in the fall here in DC area. So you'll hear more about that in the future. So that's what we hope to accomplish in the next two days. It's a big agenda. And we really look forward to a very interactive discussion. There are presentations that people will use to kick off. But we really, the most important thing that we've found in all the genomic medicine meetings are the discussions that happen around that. So with that introduction, Teri or Eric, do you want to make any comments? Sure. Well, and thanks for that nice introduction, Rex. I think you've covered the most important points except for one, which is that we are being videotaped so that you all are aware of that. Actually, we're being live streamed. So if you're somewhat schizophrenic as I am and want to watch yourself on the live streaming while you're talking, feel free to do that. We will make all of these videos available after work. So, Eric, would you like to say anything? I just want to express my appreciation to Rex and Teri for organizing this meeting, as you see, as a series. The series is, in many ways, overseen. And sort of the long-term planning of this falls under the auspices of a standing working group we now have, a genomic medicine working group, which is a working group of the National Advisory Council for Human Genome Research, which is basically the advisory council for our institute, NHGRI. It was recognized a couple of years ago that genomic medicine being a key focal point of NHGRI's mission, that it seemed important with many new and quickly changing things going on in that area, that it was important for us to establish a working group of our council to really help be, in many ways, a scouting party, if you will, for what the needs are and how the institute can have its greatest impact. And these meetings are a major part of that scouting activity, if you will, reconnaissance activity. So we are picking areas that we think are important for us to learn about. As Rex said, we do see this as much an important convening function, where we're bringing groups together that maybe otherwise wouldn't be getting together in a meeting and seeing if common areas emerge from that or common things that we could be doing and being helpful. So we very much want your input. I know the members of the working group who are here would be very interested in any feedback about things that they could be doing as a working group that NHGRI could be doing as an NIH institute. So I look forward to the next couple of days. Thank you for coming. Yeah, so just so that people at least can put a name with the face, we'd like to do a very brief round of introductions with everybody here. Obviously, that would take a long time if you just said much more than name, rank, and serial number. So if you could just indicate who you are, institution you're here representing, that would be very helpful. And we'll start at the front of the inner table. So I'm Larry Myron, I'm with the VA. Cecilie Sessions, Air Force Medical Support Agency. Steve Furrow, CMS. Liz Mansfield, FDA. Carolyn Clancy, Agency for Healthcare Research and Quality, or ARC. Wayne Currie, Center for Disease Control and Prevention. Lean, Cleveland Clinic Foundation. Murray Brilliant, Marshfield Clinic Research Foundation. Eric Green, NHGRI. Terry Minolia, Division of Genomic Medicine at NHGRI. Rex Chisholm, Northwestern University in Chicago. Jeff Ginsburg, Duke University. Brad Ozenberger, NHGRI, Division of Genomic Medicine. Mark Williams, Geisinger Health System. Dan Rodin, Vanderbilt. Good morning, Weyman Sheetam, US Navy Medicine. Good morning, Bruce Dahl, Navy Medicine. Jonathan Forsberg, Naval Medical Research Center. Deborah Leonard, University of Vermont College of Medicine, representing the College of American Pathologists. Naomi Aronson, Blue Cross and Blue Shield Association. Rhonda Cooper DeHoff, University of Florida. James Hoffman, St. Jude Children's Research Hospital. Robert Skasky, VA, Office of Research and Development. Adam Berger, Institute of Medicine. Joan Scott, National Coalition for Health, Professional Education and Genetics. Federico Nascente, University of North Carolina. Amanda Elsie, University of Florida. Klesson Turner, Walter Reed, National Military Medical Center. Mary Williams, Association for Molecular Pathology. Kristen Maloney, University of Maryland. Morah Dollymore, Coast Guard, Health Safety, Work Life. Jeff Salvin, Harmon, Coast Guard, Operational Medicine. Farwin Bodinger, Icon School of Medicine at Mount Sinai. Mark Retain, University of Chicago. Thomas Lane, INMH. David Ledbetter, Geisinger Health System. Maureen Smith, Northwestern University. Katherine Wittkopp, Air Force Medical Support Agency. Ian Marperie, NHGRI. Rognini, NHGRI. Lynn Dressler, Mission Health, Asheville, North Carolina. Tim Wiltshire, University of North Carolina. Peter O'Donnell, University of Chicago. Ronald Miller, Working with the Air Force. Janet Williams, Geisinger Health System. Jean Jenkins, NHGRI. Iftacard Colul, Mayo Clinic. Anastasia Wise, NHGRI. Eric Skolls, NHGRI. Sarah Harding, CMS. Scott Devine, University of Maryland. Sarah Knight, Department of Veterans Affairs. Mike Heathcote, Northwestern University. And if you need anything in order the next two days, you can contact me. Pearl. Pearl at Work Partners, Health Care Boston. Monica Giovanni, Geisinger Medical Center. I think we've caught everybody. Is there anybody we missed? Was there anybody we missed who just came in? All right. Then we will move on with the agenda and introduce Jeff Ginsberg from Duke University, who is going to talk about the value of an integrated strategy.